Compare TGLS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | ZYME |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | TGLS | ZYME |
|---|---|---|
| Price | $53.33 | $23.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $80.00 | $32.75 |
| AVG Volume (30 Days) | 275.8K | ★ 590.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.04 | $63.10 |
| Revenue Next Year | $10.69 | $93.26 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.26 | $9.03 |
| 52 Week High | $90.34 | $28.49 |
| Indicator | TGLS | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 58.39 | 48.12 |
| Support Level | $47.28 | $22.07 |
| Resistance Level | $54.85 | $23.52 |
| Average True Range (ATR) | 1.79 | 0.88 |
| MACD | 0.37 | 0.09 |
| Stochastic Oscillator | 79.00 | 60.44 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.